论文信息 - For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity

For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity

Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection. See related article by Bhatia et al., p. 1185

I. Melero | I. Márquez-Rodas | A. Calles | M. A. Aznar

[1] R. Coffman,et al. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. , 2018, Cancer discovery.

[2] D. Byrd,et al. Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma , 2018, Clinical Cancer Research.

[3] J. Kirkwood,et al. Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma , 2018, Clinical Trials.

[4] W. Loging,et al. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial , 2018, Clinical Cancer Research.

[5] I. Melero,et al. LBA20Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial , 2017 .

[6] M. Shi,et al. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways , 2017, International journal of molecular sciences.

[7] N. Tinari,et al. Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally , 2017, The Journal of Immunology.